PCSK9 Inhibitors Still Burdened by High Cost Despite FOURIER PCSK9 Inhibitors Still Burdened by High Cost Despite FOURIER

"These drugs have achieved the dubious distinction of being the most expensive preventive therapies by far in the history of cardiovascular medicine," says an editorial.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news